Combining Ofev (nintedanib, marketed by Boehringer Ingelheim) with…
Ana Pena, PhD
Ana is a molecular biologist with a passion for communication and healthcare innovation. As a science writer she looks for connecting the public, in particular patient and healthcare communities, with clear and quality information about the latest medical advances. Ana holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in genetics, molecular biology, and infectious diseases
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Ana Pena, PhD
Pliant Therapeutics announced that its lead therapy candidate PLN-74809 was designated an orphan…
Adding Ofev (nintedanib) to Esbriet…
The presence of swollen lymph nodes in patients with idiopathic pulmonary fibrosis (IPF)…
A new nanocarrier has been developed that is able to selectively deliver medicines to damaged cells in the…
A team of researchers at the University of California San Diego School of Medicine was recently…
Treatment with regulatory T-cells (Tregs), a subset of cells from the immune system, is able to resolve lung…
Combo Therapy Seen to Enhance Anti-Fibrotic Activity in Lung Cells from IPF Patients in Early Study
A combined treatment, pirfenidone and rapamycin, worked to prevent fibrosis in lung fibroblasts from patients…